Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX319 vs EU-Phesgo in Neoadjuvant Therapy of HER2-Positive Breast Cancer
NCT07601620Phase 1Not yet recruiting
- Sponsor
- Henlius
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of HLX319 in breast cancer (2 arms), sponsored by Henlius. Primary endpoints: Peak concentration up to 180 days, Area under the serum drug concentration-time curve from 0 to 21 days and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HLX319
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07601620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601620.